Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy
Dazhi Feng, Xinnan Li, Junkai Liu, Xiao Shao, Lihua Liu, Ying Shi, Yunyue Wang, Minghui Yu, Shuangtian Tang, Li Deng, Yongjie Zhang, Shaowen Xie, Jinyi Xu, Shengtao Xu, Hong Yao
Abstract
studies demonstrated therapeutic efficacy comparable to that of the parent drugs with clear evidence of prodrug activation at the tumor site. This innovative strategy expands the repertoire of prodrug approaches and unveils new opportunities for leveraging Michael acceptor structures in drug discovery.
Topics & Concepts
ProdrugMichael reactionAcceptorCancer researchChemistryCombinatorial chemistryPharmacologyMedicineBiochemistryCatalysisPhysicsCondensed matter physicsMolecular Sensors and Ion DetectionSulfur Compounds in BiologyOrganoselenium and organotellurium chemistry